Sialic Acid Mucosal Compositions for Blocking SARS-CoV-2 Attachment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for safe and effective compositions to inhibit or treat infections caused by SARS-CoV-2, which can lead to COVID-19, particularly in individuals at higher risk.
Innovation Solution
The use of sialic acid compositions, such as N-acetylneuraminic acid (NANA), administered in effective concentrations, either intranasally or orally, to increase the natural content of sialic acid in mucosal surfaces, thereby inhibiting viral attachment and infection by competing with cellular receptors for virus binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If sialic acid compositions are administered to inhibit SARS-CoV-2 infection, then viral attachment and infection are reduced, but the complexity of formulation and administration increases
Solution Approach 1:
The patent optimizes parameters such as sialic acid concentration (0.1-100 mg/ml), pH (2.0-4.0), and administration frequency (2-8 times per day) to achieve effective viral inhibition while managing formulation complexity. By establishing specific parameter ranges, the invention transforms a potentially complex treatment into a standardized protocol with defined characteristics.
Solution Approach 2:
The sialic acid composition acts as an intermediary substance that competitively binds to viral attachment receptors on cellular surfaces, preventing direct viral entry into cells. This mediator mechanism simplifies the treatment approach by using a small molecule that interferes with the virus-cell interaction without requiring complex delivery systems.
2Reliability
If sialic acid is administered at high concentrations to maximize viral blocking, then infection inhibition improves, but safety and tolerability concerns increase
Solution Approach 1:
The patent identifies and optimizes the therapeutic window by establishing safe concentration ranges (0.1-100 mg/ml) and pH levels (2.0-4.0) that achieve effective viral blocking while maintaining safety. The formulation parameters are adjusted to balance antiviral efficacy with tolerability, avoiding concentrations that cause adverse effects.
Solution Approach 2:
Sialic acid is a naturally occurring substance found in human tissues, and the composition leverages this biological compatibility to achieve therapeutic effects without significant toxicity. The body's natural presence of sialic acid on cell surfaces provides a basis for safe administration, as the substance is already part of normal physiological function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Sialic acid compositions effectively reduce the risk of SARS-CoV-2 infection by blocking viral attachment to epithelial cells, providing prophylactic and therapeutic benefits, especially for high-risk individuals.
Implementation Method 1
increasing the natural content of sialic acid in mucosal surfaces, thereby inhibiting viral attachment and infection by competing with cellular receptors for virus binding
Data Source
AI summary
The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).